medwireNews: The combination of carfilzomib and dexamethasone should be considered a standard of care in patients with relapsed or refractory multiple myeloma, say researchers who conducted a head to head comparison with bortezomib plus dexamethasone.
A previous analysis of the phase III ENDEAVOR trial showed that carfilzomib treatment was associated with longer progression-free survival and higher objective response rate than bortezomib, and the current analysis also shows an overall survival (OS) advantage.
Median OS was 47.6 months for the 464 patients who were randomly assigned to the carfilzomib group and 40.0 months for the 465 in the bortezomib group, a significant difference equating to a hazard ratio of 0.79.
The safety profile of carfilzomib was similar to that seen in the previous analysis, Meletios Dimopoulos (National and Kapodistrian University of Athens, Greece) and co-investigators report in The Lancet Oncology.
And they conclude that given the large number of treatment options available in this setting, the ENDEAVOR findings could help physicians decide which proteasome inhibitor to use.
medwireNews is an independent medical news service provided by Springer Healthcare. © 2017 Springer Healthcare part of the Springer Nature group